Revenue: Total Q1 sales reached £7.6 billion, representing a 5% increase at constant exchange rates (CER). At this growth rate, the top line is tracking comfortably within the firm’s projected 3% to 5% full-year target, despite adverse sterling movements against the dollar.

Profit & Margins: Core operating profit grew 10% CER to £2.65 billion, translating to a core operating margin expansion of 1.8 percentage points to 34.7%. This profitability beat was fuelled by a favourable regional product mix, higher royalty income, and disciplined SG&A spending.

Cash & Balance Sheet: Cash generated from operations stood at a healthy £1.4 billion, yielding £800 million in free cash flow. This gives the pharmaceutical giant ample balance sheet flexibility to continue R&D investments and pursue bolt-on pipeline acquisitions.

Management remains highly committed to returning capital, declaring a Q1 dividend of 17p per share with a clear path toward a 70p full-year payout. Furthermore, the company has already executed £1.7 billion of its £2 billion share buyback programme initiated last year.

Driver Breakdown Box

• Specialty Medicines Surge: The segment jumped 14% to £3.2 billion, heavily lifted by Oncology sales (+28%) and Respiratory, Immunology & Inflammation (+16%).
• Vaccine Resilience: Vaccines posted a 4% gain to £2.1 billion, anchored by a massive £1.0 billion contribution from Shingrix (+20%), which successfully offset a steep 18% decline in Arexvy.
• Tariff Relief: A definitive agreement with the US Government shields GSK and ViiV Healthcare from Section 232 tariffs through January 2029, removing a significant overhang on future gross margins.

AskTraders Takeaway: So what does this mean for the stock? The 1.9% dip in shares likely reflects broader macroeconomic positioning and minor market concerns over the 6% contraction in General Medicines, rather than a fundamental flaw in the Q1 print. The reaffirmed guidance highlights underlying operational stability, making the post-earnings pullback a potential area of interest for value-oriented participants.

Watch the R&D pipeline progression into the second half of the year. With regulatory filings accepted for bepirovirsen—a potential functional cure for chronic hepatitis B—and updated Phase III plans for oncology ADCs, clinical execution could serve as a major upside catalyst.

CEO Luke Miels stated, “GSK has made a strong start to 2026, with good performance from our key growth drivers,” reinforcing the company’s focus on execution and accelerating R&D through strategic acquisitions like ozureprubart for food allergies.

Analyst Summary: Bull and Bear Cases

The post GSK Posts Solid Q1 Sales and Reaffirms 2026 Guidance appeared first on AskTraders.com.

Revenue: Group like-for-like sales expanded by a robust 4.8%, demonstrating resilience against a sluggish broader retail backdrop. This top-line momentum was anchored by a 4.1% rise in Retail LfL sales and a standout 5.8% increase in Autocentres, excluding the Avayler software business.

Profit & Margins: FY26 underlying PBT is now projected to hit the upper bound of the £36.0 million to £41.2 million consensus range. This profitability upgrade is directly attributed to sustained gross margin expansion and disciplined, well-managed operational costs throughout the fiscal year.

Cash & Balance Sheet: The Group remains highly cash generative, successfully closing the financial period to April 3 in a definitive net cash position.

Transitioning to a net cash position provides Halfords with significant balance sheet flexibility. For markets, this signals a fundamentally de-risked financial profile.

The robust liquidity not only fortifies the company against broader macroeconomic uncertainties but also paves the way for potential shareholder value enhancements. This could materialize through progressive dividend distributions or targeted capital expenditures aimed at expanding the high-margin Autocentres division.

Driver Breakdown

• Cycling Resurgence: Retail Cycling LfL sales jumped 6.4%, indicating a strong recovery and resilient consumer demand in a segment that has historically faced post-pandemic volatility.
• Service Sector Momentum: The garage services arm delivered a 5.8% LfL growth, reinforcing the strategic pivot toward non-discretionary, service-based revenues that offer higher margins and recurring customer touchpoints.
• Proactive Cost Hedging: The majority of FY27 energy costs, foreign exchange requirements, and freight rates are already contracted in advance. This foresight severely limits near-term margin erosion from global supply chain shocks.

The 10% upward repricing reflects market relief over both the FY26 profit beat and the highly confident FY27 outlook. While conflict in the Middle East continues to create an uncertain macroeconomic backdrop, Halfords confirmed that trading through March and April remained strictly in line with expectations.

By successfully hedging major input costs, the retailer has effectively insulated its bottom line, allowing management to comfortably back FY27 underlying PBT consensus estimates of £42.0 million to £48.6 million.

CEO Henry Birch stated, “I am pleased to see the positive results that are starting to materialise from the ‘optimise’ phase of our ‘Fit for the Future’ strategy as we focus on driving operational excellence and strengthening our foundations for future growth,” reinforcing the company’s focus on internal efficiencies and thanking the 12,500 staff members who executed the vision.

The post Halfords Shares Surge 10% as FY26 Profit Tracks Toward Upper End of Expectations appeared first on AskTraders.com.

While North America finally returned to growth, the broader respiratory drag has prompted markets to adopt a cautious stance, sending shares slightly lower despite management reiterating full-year guidance.

Reported revenue came in flat at £2.86 billion, translating to a mere 0.1% reported growth year-over-year. Organic growth of 2.2% was driven entirely by a 2.4% pricing increase, which barely offset a slight 0.2% volume contraction.

While specific Q1 profit figures were omitted from the trading update, core supply chain productivity initiatives continue to drive gross margin expansion. This operational efficiency supports the reiterated target of high-single-digit adjusted operating profit growth at constant currency for the fiscal year.

Capital allocation remains highly disciplined, with the company progressing steadily on its £500 million share buyback program for 2026.

Haleon’s commitment to shareholder returns remains a bright spot amidst the top-line deceleration. The consumer healthcare giant has already completed approximately 36% of its £500 million share buyback allocation for the year.

This ongoing repurchasing activity provides a vital floor for the stock, signaling management’s confidence in cash generation and long-term value creation even as external macroeconomic headwinds and volume pressures persist.

Driver Breakdown Box:

• Respiratory Drag: A notably weak cold and flu season shaved an estimated 130 basis points off total organic growth, pushing overall Respiratory Health category revenues down 3.4% for the quarter.
• Oral Health Outperformance: Sensodyne and parodontax continue to command strong pricing power and market share. Continuous innovation rollouts across the clinical platform drove an impressive 8.3% organic growth in the Oral Health division.
• North American Recovery: Despite the respiratory headwinds, the critical North American market returned to positive territory with 1.0% organic revenue growth, indicating that broader brand activations and strategic growth initiatives are successfully gaining traction.

AskTraders Takeaway:

The Q1 print paints a picture of a resilient, diversified portfolio masking localized seasonal weakness. Markets are currently fixating on the slight volume contraction and the respiratory segment’s drag on the top line. However, underlying operational leverage remains firmly intact. With gross margins expanding and the foreign exchange translation impact now expected to be broadly neutral for the year, profitability metrics are shielded. Volatility may persist in the near term as markets digest the sluggish volumes, but the reiterated 3-5% full-year organic growth target suggests management anticipates a steeper acceleration in the back half of the year.

CEO Brian McNamara stated, “We delivered a competitive performance in a challenging market, with North America returning to growth and Oral Health again performing strongly… tempered by a weak cold and flu season,” reinforcing the company’s focus on productivity initiatives and geographic expansion to drive agility.

Eyes On: Watch margin expansion closely in the upcoming quarters—if supply chain productivity continues to outpace inflation, it could fuel a sustained rally regardless of seasonal top-line fluctuations.

The post Haleon Shares Edge Lower as Weak Cold and Flu Season Weighs on Q1 Sales appeared first on AskTraders.com.

Despite the solid fundamental performance and resilient credit metrics, markets reacted with mild skepticism, sending shares down approximately 1.2% in the early part of the session.

Underlying net interest income hit £3.6 billion, up 8% year-on-year. At this growth rate, the bank is comfortably tracking toward its reiterated 2026 guidance of greater than £14.9 billion in net interest income, supported by underlying other income of £1.6 billion.

Statutory profit before tax jumped to £2.0 billion from £1.5 billion a year ago. Core profitability metrics were exceptional, translating to a return on tangible equity of 17.0% and an improved cost:income ratio of 51.9%.

The CET1 ratio stands at a healthy 13.4% after ordinary dividend accruals, giving the bank ample flexibility for future distributions. Tangible net assets per share expanded to 57.9 pence, up 0.9 pence for the quarter.

The strong capital generation of 41 basis points highlights Lloyds’ ongoing capacity to drive shareholder value. The bank remains structurally positioned to support ongoing dividends and share buybacks, as evidenced by management’s stated goal to optimize the CET1 ratio down to approximately 13.0%.

However, a slight £0.6 billion dip in customer deposits to £495.9 billion, alongside a 10% jump in operating lease depreciation to £389 million due to declining used car prices, may be giving markets a reason to trim positions. This underlying friction likely explains the current 1.2% slide in the share price despite the top-line beat.

Driver Breakdown

• Net Interest Margin Expansion: NIM expanded by 14 basis points year-on-year to 3.17%, fueled by strong structural hedge income and targeted franchise volume growth.
• Strict Cost Discipline: Operating costs declined by 3% to £2.5 billion. Lower severance expenses and structural cost savings successfully offset broader inflationary pressures and business growth investments.
• Resilient Asset Quality: The underlying impairment charge of £295 million resulted in an asset quality ratio of just 25 basis points. This reflects a stable credit environment, even after factoring in a £101 million net charge from updated multiple economic scenarios.

CEO Charlie Nunn stated, ‘We are confident in our delivery for the year ahead and reiterate our guidance for 2026. We look forward to presenting our new strategy alongside the half-year results.’, reinforcing the company’s strategic momentum and commitment to supporting UK households.

The post Lloyds Banking Group Posts Strong Q1 Profit, But Shares Dip—Here’s Why You Should Care appeared first on AskTraders.com.

Shares opened lower on cautious forward-looking commentary regarding the Middle East, but markets quickly digested the strong balance sheet, sending the stock up over 1% in mid-morning trading.

A burst of volume post-print suggests early morning short-covering could extend into tomorrow’s session, as the initial knee-jerk reaction to geopolitical commentary was swiftly bought up by value-seeking market participants.

Profit & Margins: The group expects to report an operating profit between £435m and £440m, stepping down slightly from FY25’s £446.5m. This figure comfortably absorbs £11m in promotional and resourcing startup costs tied to the highly anticipated London Gatwick base launch.

Cash & Balance Sheet: Total cash stands at a formidable £3.3bn with net cash at £2.0bn. The airline also retains access to an undrawn £500m Revolving Credit Facility, providing robust liquidity to navigate cyclical headwinds.

The fortress balance sheet is doing exactly what it was designed to do—insulating the company from short-term macro volatility while actively rewarding equity holders. Jet2 successfully returned £363.0m of capital to shareholders during the fiscal year.

That disciplined capital allocation, combined with sustained investments in future growth, signals a management team highly focused on long-term shareholder value creation rather than just weather-proofing the current quarter.

Driver Breakdown

• Gatwick Expansion: The operational launch at London Gatwick marks Jet2’s entry into the UK’s biggest holiday airport, bringing 90% of the British public within a 90-minute drive of a Jet2 base.
• Capacity & Bookings: Summer 2026 on-sale capacity is up 7.7% to 19.9m seats, with booked-to-date passengers rising 6.2% across both package holidays and flight-only segments.
• Cost Certainty: The group boasts a highly defensive hedged position, locking in 87% of its summer requirement with jet fuel swaps at an average price of $707 per metric tonne.

AskTraders Takeaway: Markets initially balked at the disclosure that geopolitical uncertainty in the Middle East is pushing the booking profile increasingly close to departure dates.

Watch the combined average load factor in Q1; maintaining parity with the prior year despite late bookings will be critical to sustaining this equity rally. Fortunately, short-term volatility is largely mitigated by the airline’s aggressive fuel hedging and expansive £2.0bn net cash buffer, allowing them to remain fully committed to attractive pricing without sacrificing margins.

CEO Steve Heapy stated, “FY26 was another strong year for Jet2, topped off by the successful launch of operations at London Gatwick which is performing ahead of our initial expectations with over 0.4m passengers booked for the summer season,” reinforcing the company’s customer-focused and service-led business model.

Analyst Summary: Bull and Bear Cases

The post Jet2 Hits FY26 Targets Amid Geopolitical Uncertainty—Here’s Why Markets Are Buying The Dip appeared first on AskTraders.com.

The case centers on whether federal pesticide law preempts state-law failure-to-warn claims related to Bayer’s Roundup weedkiller.

In a note, mwb Research explained that Missouri plaintiff John Durnell secured a $1.25 million verdict linking Roundup exposure to non-Hodgkin lymphoma, with Bayer arguing that repeated U.S. EPA findings of glyphosate’s non-carcinogenic nature should prevent state juries from imposing additional warning requirements.

Justices are said to have appeared divided, with a final ruling expected by end of June.

Analyst Abed Jarad acknowledged the hearing provided no decisive outcome but framed it as continued progress in Bayer’s broader litigation containment strategy.

“While oral arguments did not provide a decisive read-through, Supreme Court pre-emption remains a credible catalyst,” Jarad wrote, noting that a favorable ruling, combined with the pending $7.25 billion class settlement, would improve visibility around what mwb Research describes as Bayer’s largest structural overhang.

The firm was careful to temper expectations, noting that even a favorable ruling “would not eliminate all litigation immediately,” given residual non-label-based claims.

Nevertheless, mwb Research argued that “the market still over-discounts prolonged litigation drag,” and sees scope for balance sheet normalization and multiple re-rating as legal milestones are executed.

Bayer shares closed Tuesday’s session at €36.62 after a 4.6% decline.

The post Analyst Stays Bullish on Bayer as Supreme Court Hearing Offers Cautious Hope appeared first on AskTraders.com.

The moving average picture is notably split. Of the key moving averages tracked, eight are currently issuing sell signals against just five buys, with one neutral reading, suggesting a bearish skew driven predominantly by the shorter-duration averages crossing into negative territory.

This suggests recent price weakness has been sufficient to drag near-term trend indicators lower, even as the longer-dated moving averages, which carry the memory of the index’s stronger performance over prior months, continue to point upward.

The divergence between short and long-term averages is a hallmark of a market in transition, where momentum has faded but the broader structural trend has not yet broken down.

Oscillators offer little clarity. Of the eleven tracked, seven are reading neutral, while two are signalling sell and two signal buy, a distribution that reflects an index neither meaningfully overbought nor oversold.

The absence of a strong directional lean from momentum indicators suggests buying pressure and selling pressure are broadly in balance, with no clear catalyst yet to break the deadlock.

The overall technical summary sits at neutral, with ten sell signals, eight neutral and seven buys across all indicators combined, a picture of an index waiting for a decisive push in either direction.

The post FTSE 100 Caught in Technical Tug-of-War as Mixed Signals Point to Near-Term Uncertainty appeared first on AskTraders.com.

The energy group posted first-quarter underlying replacement cost profit of $3.2 billion, up from $1.5 billion in the fourth quarter of 2025. Reported profit surged to $3.8 billion, compared with a loss of $3.4 billion in the previous quarter, helped by exceptional oil trading results and stronger midstream performance.

Plant reliability in the upstream division improved to 95.7%, while refining availability rose to 96.3%, exceeding the company’s 96% target. Production held broadly steady, with higher output in the Gulf of America and from bpx Energy offsetting Middle East disruptions and a North Sea divestment.

Chief executive Meg O’Neill said: “This was another quarter of strong operational and financial delivery, and we made further progress towards our 2027 targets.” She added that the company is “keeping production levels steady despite the ongoing disruption.”

Operating cash flow came in at $2.9 billion after a $6 billion working-capital build driven by seasonal effects and rising commodity prices. Net debt increased to $25.3 billion from $22.2 billion at the end of 2025, reflecting the lower cash flow. Capital expenditure totaled $3.3 billion during the quarter.

O’Neill said BP is “heading in the right direction, strengthening the balance sheet and continuing to accelerate delivery,” noting plans to simplify operations and improve returns as the company progresses toward its 2027 goals.

The company maintained its dividend at 8.32 cents per share and reiterated its 2026 capital expenditure guidance of $13 billion to $13.5 billion.

The post BP Shares Rise as Profit Jumps Following Strong Q1 Performance appeared first on AskTraders.com.

The lender posted a return on tangible equity (RoTE) of 13.5% for the first quarter of 2026, down slightly from 14.0% a year earlier, while earnings per share rose 8% to 14.1p. Profit before tax increased to £2.8 billion from £2.7 billion, supported by a 6% rise in group income to £8.2 billion.

Chief executive C. S. Venkatakrishnan said: “Barclays delivered another solid quarter with a 13.5% RoTE in Q126, and double-digit returns in all our businesses.”

He added that income growth was “driven by broad based divisional performance including in the Investment Bank, where we generated over £4bn quarterly income for the first time.”

However, results were impacted by higher impairments, with credit charges rising to £0.8 billion and the loan loss rate increasing to 74 basis points. This included a £200 million single-name impairment in the investment bank. The bank also recorded a £100 million litigation and conduct charge, “primarily reflected an increase in the provision for the UK Financial Conduct Authority (FCA) motor finance redress scheme”.

Despite these headwinds, Barclays improved its cost:income ratio to 56% and maintained a strong capital position, with a CET1 ratio of 14.1%. The bank reiterated its targets, including a RoTE above 12% in 2026.

Barclays said it remains confident in delivering its medium-term goals, supported by “the breadth and quality” of its businesses.

The post Barclays Shares Lower Despite Solid Q1 Results and £500m Buyback appeared first on AskTraders.com.

The FTSE 250 is down 0.4%, while Germany’s DAX is up 0.1% and France’s CAC 40 has gained 0.2%.

BP leads the FTSE 100 risers, up 2.4%, after reporting first-quarter profits of $3.2 billion, driven by an exceptional performance in its oil trading business in the months following the outbreak of the Iran war.

Shell is also among the top gainers, rising 1.5%, with Diploma up 1.6%.

Barclays is the biggest faller, dropping 3.1% despite reporting a 6% rise in first-quarter total income to £8.2 billion, narrowly ahead of consensus forecasts. The bank announced a further £500 million share buyback but also booked a £228 million provision linked to collapsed lender MFS, which appears to have unsettled investors.

Compass Group and Persimmon are both down 1.7%.

Overall, sentiment remains fragile as diplomatic efforts in the Middle East show little sign of progress, with the continued closure of the Strait of Hormuz keeping energy markets on edge and broader indices caught between corporate earnings optimism and geopolitical uncertainty.

The post FTSE 100 Edges Higher Despite Continued Geopolitical Uncertainty; Shell and BP Shares Rise appeared first on AskTraders.com.

Trading at around 97.5p, the stock sits below its February 4 high of 114.6p, and momentum measures suggest the retreat may not yet be over.

The daily buy/sell signal has deteriorated, with the technical summary now reading as a sell across key timeframes, including the hourly, 4-hourly, and daily.

The picture painted by moving averages is equally cautious. Both short and long-term moving averages on the daily chart are issuing sell signals, according to TradingView data, with the long-term average sitting above the short-term average, a bearish crossover configuration.

Resistance levels are clearly defined, with overhead supply clustered around 105.2p, meaning any recovery rallies are likely to encounter selling pressure before those marks are cleared.

Oscillators are adding to the gloom, with momentum readings hovering in neutral-to-negative territory, suggesting the stock lacks the buying conviction needed to stage a meaningful reversal.

The MACD on the weekly timeframe is also in sell territory, reinforcing the broader downtrend. While pivot point support sits around 105.97p, bulls will need to reclaim that level convincingly to shift the technical narrative back in their favour.

The post Lloyds Shares: Technical Indicators Turning Bearish appeared first on AskTraders.com.

Under the terms of the deal, ARC shareholders will receive CAD 8.20 in cash plus 0.40247 Shell ordinary shares per share, a blended consideration of CAD 32.80, representing a 20% premium to ARC’s 30-day volume-weighted average price.

The transaction is structured roughly 25% in cash and 75% in Shell stock, with around 228 million new Shell shares to be issued.

Shell says the acquisition accelerates its production growth rate from 1% to 4% compound annual growth rate through to 2030, adding 370 thousand barrels of oil equivalent per day from ARC’s Montney shale operations in British Columbia and Alberta.

The deal also bolsters Shell’s LNG Canada ambitions, given ARC’s gas reserves and proximity to Shell’s existing Groundbirch asset.

However, in a note following the news, Jefferies analysts expressed surprise at the deal’s timing.

The investment bank had expected ARC’s strong free cash flow generation and solid balance sheet to give management ample time to resolve operational challenges at its Attachie development project.

The firm suggested that agreeing to sell now could signal Attachie requires a longer resolution timeline than previously anticipated. Despite the reservations around timing, Jefferies maintained its Buy rating on ARC shares with a C$30 price target.

The transaction is expected to close in the second half of 2026.

The post Shell Announces $16.4bn ARC Resources Takeover – Jefferies Questions Timing appeared first on AskTraders.com.